UNICREDIT BANK/CALL/VERTEX PHARMACEUTICALS/500/0.1/15.01.25 | Real-time BOERSE MUENCHEN 16:42:03 27/06/2024 BST | ||
| 3.12 EUR | +0.65% |
|
| Current month | +15.67% | ||
| 1 month | +13.55% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 27/06/24 | 3.12 | +0.65% |
| 26/06/24 | 3.1 | +0.65% |
| 25/06/24 | 3.08 | -4.94% |
| 24/06/24 | 3.24 | +9.09% |
| 21/06/24 | 2.97 | -5.11% |
Real-time BOERSE MUENCHEN
Last update June 27, 2024 at 04:42 pm
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | 
UniCredit
|
| WKN | HC5VER |
| ISIN | DE000HC5VER9 |
| Date issued | 11/04/2023 |
| Strike | 500 $ |
| Maturity | 15/01/2025 (202 Days) |
| Parity | 10 : 1 |
| Emission price | 2.05 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 4.24 € |
|---|---|
| Lowest since issue | 1.01 € |
| Spread | 0.04 € |
| Spread % | 1.27% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
32
Last Close Price
474
USD
Average target price
468.3
USD
Spread / Average Target
-1.21%
- Stock Market
- Warrants
- Warrant
